• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical

Clearside Biomedical misses Q3 earnings estimates

November 8, 2017 By Sarah Faulkner

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the company missed expectations on Wall Street with its third quarter results. The Alpharetta, Ga.-based company posted a net loss of -$18.3 million for the 3 months ended Sept. 30, for bottom-line loss of -226% compared with the same period last year. Adjusted to exclude 1-time items, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical misses EPS estimate in Q2

August 9, 2017 By Sarah Faulkner

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) fell slightly today after the biopharmaceutical company missed earnings expectations on Wall Street with its second quarter results. The Alpharetta, Ga.-based company posted a net loss of -$13.8 million on sales of $130,000 for the 3 months ended June 30, for bottom-line loss of -169% compared with the same period last year. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical launches Phase II diabetic macular edema trial

July 12, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Patients with DME will either receive […]

Filed Under: Clinical Trials, Diabetes, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical highlights preliminary data from retreatment trial

June 8, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration. Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion. The company’s Phase II […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Clearside Biomedical

Clearside Biomedical beats Q1 earnings consensus

May 11, 2017 By Sarah Faulkner

Clearside Biomedical

Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 1st quarter results. The Alpharetta, Ga.-based company posted a net loss of -$10.4 million, or -41¢ per share, on sales of $5,000 for the 3 months ended March 31, for bottom-line loss of -47.5 % compared with […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic Tagged With: Clearside Biomedical

Clearside closes patient enrollment in trial for diabetic macular edema therapy

April 20, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema. The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical

Clearside inks clinical development deal with EyeKor

March 31, 2017 By Sarah Faulkner

Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement. Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical, EyeKor

Clearside bails on AMD, all-in on diabetic macular edema

February 27, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today it will redirect its R&D efforts from its pre-clinical axitinib wet age-related macular degeneration therapy to its Zuprata diabetic macular edema treatment. The Alpharetta, Ga.-based company said that recent trial results from other companies investigating combination therapies for wet AMD have led Clearside to reconsider its proprietary suspension formulation of […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Research & Development, Wall Street Beat Tagged With: Clearside Biomedical

Clearside enrolls first patient in phase III trial of Zuprata combination therapy

February 16, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in a phase III trial evaluating Zuprata, its suspension formulation of triamcinolone acetonide, in combination with Eylea, intravitreal aflibercept, for the treatment of macular edema associated with retinal vein occlusion. The trial is slated to enroll 460 patients with retinal vein occulsion to assess […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Clearside Biomedical

Clearside Biomedical names Beckman as new CMO | Personnel Moves, Jan. 5, 2017

January 5, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) today named Dr. Richard Beckman as chief medical officer. Beckman is an ophthalmologist with 13 years of clinical practice under his belt, as well as 20 years of corporate executive and consultancy experience. Prior to joining Clearside, Beckman managed a pharmaceutical and medical device industry consulting firm. He has also served as […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Personnel Tagged With: Clearside Biomedical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS